Pharmaceutical Stocks To Research – July 14th

Verona Pharma PLC American Depositary Share, Eli Lilly and Company, Thermo Fisher Scientific, Waters, and Blueprint Medicines are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are the publicly traded shares of companies engaged in the research, development, manufacturing and marketing of prescription and over-the-counter drugs. Their performance is driven by factors such as clinical trial outcomes, regulatory approvals, patent expirations and shifts in healthcare policy and market demand. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Verona Pharma PLC American Depositary Share (VRNA)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Shares of NASDAQ VRNA traded down $0.10 during midday trading on Monday, hitting $104.73. The stock had a trading volume of 11,399,422 shares, compared to its average volume of 1,636,010. The company has a market capitalization of $8.92 billion, a price-to-earnings ratio of -52.37 and a beta of 0.24. Verona Pharma PLC American Depositary Share has a 1-year low of $18.51 and a 1-year high of $104.99. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07. The company has a fifty day moving average price of $83.89 and a 200 day moving average price of $67.97.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE LLY traded up $2.11 during midday trading on Monday, hitting $795.12. The stock had a trading volume of 1,330,345 shares, compared to its average volume of 3,666,440. The company has a market capitalization of $753.57 billion, a price-to-earnings ratio of 64.69, a PEG ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The company has a fifty day moving average price of $766.39 and a 200 day moving average price of $800.06.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of NYSE:TMO traded down $8.46 during mid-day trading on Monday, hitting $426.40. 1,914,659 shares of the company traded hands, compared to its average volume of 2,405,033. The firm has a market cap of $160.96 billion, a P/E ratio of 25.03, a PEG ratio of 2.31 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88. The firm’s 50 day simple moving average is $409.39 and its 200 day simple moving average is $475.87.

Waters (WAT)

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

WAT stock traded down $42.73 during midday trading on Monday, hitting $310.18. 2,338,958 shares of the company’s stock were exchanged, compared to its average volume of 481,093. The company has a current ratio of 1.81, a quick ratio of 1.28 and a debt-to-equity ratio of 0.69. Waters has a 12-month low of $297.14 and a 12-month high of $423.56. The firm has a 50 day moving average price of $349.62 and a 200-day moving average price of $363.50. The stock has a market capitalization of $18.46 billion, a price-to-earnings ratio of 28.15, a price-to-earnings-growth ratio of 3.49 and a beta of 1.10.

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

BPMC stock traded up $0.05 during midday trading on Monday, hitting $129.35. 5,484,269 shares of the company’s stock were exchanged, compared to its average volume of 1,402,367. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 1.01. Blueprint Medicines has a 12-month low of $73.04 and a 12-month high of $129.49. The firm has a 50 day moving average price of $117.02 and a 200-day moving average price of $101.90. The stock has a market capitalization of $8.35 billion, a price-to-earnings ratio of -52.37 and a beta of 0.89.